DCPH vs. FPRX, AGIO, SNDX, XNCR, ALXO, ROIV, INSM, LEGN, ASND, and CERE
Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Five Prime Therapeutics (FPRX), Agios Pharmaceuticals (AGIO), Syndax Pharmaceuticals (SNDX), Xencor (XNCR), ALX Oncology (ALXO), Roivant Sciences (ROIV), Insmed (INSM), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), and Cerevel Therapeutics (CERE). These companies are all part of the "medical" sector.
Five Prime Therapeutics (NASDAQ:FPRX) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
67.3% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Deciphera Pharmaceuticals had 5 more articles in the media than Five Prime Therapeutics. MarketBeat recorded 5 mentions for Deciphera Pharmaceuticals and 0 mentions for Five Prime Therapeutics. Five Prime Therapeutics' average media sentiment score of 0.87 beat Deciphera Pharmaceuticals' score of 0.00 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the news media.
Five Prime Therapeutics has higher earnings, but lower revenue than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.
Deciphera Pharmaceuticals has a consensus price target of $24.17, suggesting a potential downside of 5.47%. Given Five Prime Therapeutics' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Five Prime Therapeutics.
Deciphera Pharmaceuticals has a net margin of -108.86% compared to Deciphera Pharmaceuticals' net margin of -554.71%. Five Prime Therapeutics' return on equity of -52.42% beat Deciphera Pharmaceuticals' return on equity.
Five Prime Therapeutics has a beta of 4.4, indicating that its share price is 340% more volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Deciphera Pharmaceuticals received 15 more outperform votes than Five Prime Therapeutics when rated by MarketBeat users. Likewise, 64.91% of users gave Deciphera Pharmaceuticals an outperform vote while only 55.86% of users gave Five Prime Therapeutics an outperform vote.
Summary
Deciphera Pharmaceuticals beats Five Prime Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Deciphera Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Deciphera Pharmaceuticals Competitors List
Related Companies and Tools
